Table 3.
Summary of select comorbidities and previous PDE5 use at baseline (safety population, N=191)
Comorbidities, n (%) | |
Hypertension | 61 (32) |
Hypercholesterolaemia | 26 (14) |
Depression | 26 (14) |
Hyperlipidaemia | 20 (10) |
Diabetes | 13 (7) |
Prior PDE5 inhibitor use, n (%) | |
Sildenafil | 131 (69) |
Tadalafil | 37 (19) |
Vardenafil | 46 (24) |
PDE5, phosphodiesterase type 5.